Published in final edited form as:

Eur J Pain. 2011 October ; 15(9): 913–920. doi:10.1016/j.ejpain.2011.03.007.

Vector-mediated release of GABA attenuates pain-related behaviors and reduces Na_v1.7 in DRG neurons

Munmun Chattopadhyay, Marina Mata, and David J. Fink

Department of Neurology, University of Michigan and VA Ann Arbor Healthcare System Ann Arbor, MI, USA

Abstract

Pain is a common and debilitating accompaniment of neuropathy that occurs as a complication of diabetes. In the current study, we examined the effect of continuous release of gamma amino butyric acid (GABA), achieved by gene transfer of glutamic acid decarboxylase (GAD67) to dorsal root ganglia (DRG) in vivo using a nonreplicating herpes simplex virus (HSV)-based vector (vG) in a rat model of painful diabetic neuropathy (PDN). Subcutaneous inoculation of vG reduced mechanical hyperalgesia, thermal hyperalgesia and cold allodynia in rats with PDN. Continuous release of GABA from vector transduced cells in vivo prevented the increase in the voltage gated sodium channel isoform 1.7 (Na_v1.7) protein that is characteristic of PDN. In vitro, infection of primary DRG neurons with vG prevented the increase in Na_v1.7 resulting from exposure to hyperglycemia. The effect of vector-mediated GABA on Na_v1.7 levels *in vitro* was blocked by phaclofen but not by bicuculline, a GABA_B receptor effect that was blocked by pertussis toxin-(PTX) interference with Gα_{i/o} function. Taken in conjunction with our previous observation that continuous activation of delta opioid receptors by vector-mediated release of enkephalin also prevents the increase in Na_v1.7 in DRG exposed to hyperglycemia *in vitro* or *in vivo*, the observations in this report suggest a novel common mechanism through which activation of G protein coupled receptors (GPCR) in DRG neurons regulate the phenotype of the primary afferent.

Keywords

painful diabetic neuropathy; voltage gated sodium channels; gene transfer; gene therapy; pain; diabetes

Introduction

Neuropathy is a major complication of diabetes mellitus, and a common cause of neuropathic pain (Tavakoli et al., 2008). Like other forms of chronic neuropathic pain, painful diabetic neuropathy (PDN) is difficult to treat (Finnerup et al., 2010). In an attempt to directly target delivery of analgesic peptides to nociceptive pathways (Mata et al., 2008) we have developed a series of non-replicating herpes simplex virus (HSV)-based vectors that efficiently target gene delivery to dorsal root ganglia (DRG) from skin inoculation (Glorioso and Fink, 2004; Wolfe et al., 1999). In previous studies we have demonstrated the efficacy of HSV vectors designed to release enkephalin, endomorphin-2 or gamma aminobutyric acid (GABA) in models of inflammatory pain, central neuropathic pain, and pain caused by cancer (Goss et al., 2002; Goss et al., 2001; Hao et al., 2003; Hao et al.,

2009; Liu et al., 2004; Wolfe et al., 2007). The first of these HSV-based vectors, a non-replicating HSV vector expressing preproenkephalin is currently in clinical trial in patients with intractable pain from cancer (Wolfe et al., 2009).

The role of spinal GABA in neuropathic pain syndromes is uncertain. Several recent studies have suggested that in models of chronic pain induced by inflammation or peripheral nerve injury, a reduction in the expression of the potassium chloride cotransporter 2 (KCC2) in neurons of the superficial spinal dorsal horn may induce a shift in the effect of GABA on the GABA_A receptor from inhibitory to excitatory (Coull et al., 2003; Zhang et al., 2008) and thus contribute to the neuropathic pain phenotype (Mantyh and Hunt, 2004; Zhang et al., 2008). Despite these observations, we previously found that inoculation of an HSV vector encoding glutamic acid decarboxylase (GAD) that results in release of GABA in the dorsal horn is effective in reducing pain-related behaviors in the spinal nerve ligation model of neuropathic pain (Hao et al., 2005).

The rodent model of PDN in rats with streptozotocin (STZ)-induced diabetes is characterized by increased amounts of the voltage-gated sodium channel α subunit isoform 1.7 (Na_v1.7) in DRG (Hong et al., 2004; Hong and Wiley, 2006), an increase that occurs as a result of a post-transcriptional process mediated by protein kinase C (PKC) (Chattopadhyay et al., 2008). We previously observed that HSV-mediated expression of enkephalin in DRG of diabetic animals results in a reduction in the amount of Na_v1.7 protein in DRG neurons *in vivo*, coincident with a reduction in pain-related behaviors (Chattopadhyay et al., 2008). Because of the substantial evidence that Na_v1.7 in DRG may be a key contributor to the neuropathic pain phenotype (Dib-Hajj et al., 2007; Drenth and Waxman, 2007), the reduction of Na_v1.7 produced by delta opioid receptor (DOR) activation represents an additional effect, beyond the well-recognized effects of enkephalin as an inhibitory neurotransmitter, through which enkephalin might act to reduce neuropathic pain in PDN.

The current study was undertaken to answer two questions: 1) would HSV-mediated release of GABA from primary afferents reduce neuropathic pain in rats with PDN; and 2) would HSV-mediated release of GABA reduce Na_v1.7 protein levels in the DRG of rats with PDN?

Materials and methods

Vector construct—The non-replicating HSV vector vG is defective in expression of the HSV immediate early (IE) genes ICP4, ICP22, ICP2 and ICP47 and contains the human GAD67 gene under the control of the human cytomegalovirus immediate early promoter (HCMV IEP) in the UL41 locus. Construction and characterization of this vector has been previously described (referred to as QHGAD67 in (Liu et al., 2004)). Control vector vZ is identical to vG except that it contains the *E. coli lacZ* reporter gene under the control of the HCMV IEP in the HSV tk locus (referred to as Q0ZHG in (Liu et al., 2004)).

Animal Studies—All the experiments were conducted on young adult male Sprague Dawley rats weighing 200–250 g (Charles River; Portage, MI USA) at the start of the experiment, and were in compliance with approved institutional animal care and use protocols and in conformance with the ethical standards of the AAALAC and IASP. Rats were rendered diabetic by injection of streptozotocin (STZ; 50 mg/kg, ip; Sigma, St Louis, MO, USA). The average blood glucose levels of animals in the study were $522 \pm 12/9$ mg/dl in the diabetic group and 140 ± 9 mg/dl in the control group. At 2 weeks after injection of STZ, groups of 10 rats were injected with 30 μ l containing 1×10^7 plaque forming units (pfu) of either of vG, vZ, or a similar volume of vehicle alone subcutaneously into the

plantar surface of both hind feet. 10 animals that did not receive STZ served as normal controls. All analyses were carried out by an observer blinded to the treatment group 4 weeks after vector inoculation (at 6 weeks of diabetes). A separate group of rats were injected in a similar fashion with vG and sacrificed by perfusion 7 days later for the studies of transgene expression *in vivo*.

Behavioral studies

Thermal hyperalgesia—The latency to hind paw withdrawal from a thermal stimulus was determined by exposing the plantar surface of the hind paw to radiant heat using a modified Hargreaves thermal testing device (Hargreaves et al., 1988) as described (Chattopadhyay et al., 2008).

Mechanical hyperalgesia—Mechanical nociceptive threshold was assessed using an analgesimeter (Ugo Basile, Comerio, VA, Italy) (Chattopadhyay et al., 2008; Randall and Sellito, 1957).

Cold allodynia—Cold allodynia was assessed by withdrawal from acetone spray, as described (Chattopadhyay et al., 2008).

Adult DRG culture—DRG were removed from adult female rats, treated with collagenase (0.25%, Sigma, St Louis, MO, USA) for 1 hr at 37° C and then dissociated with 2.5% trypsin (Sigma) in 1 mmol/l ethylene-diaminetetraacetic acid (EDTA; Sigma) for 30 min at 37° C before being plated on laminin, poly-D-lysine-coated coverslips at 10⁵ cells per well in a 24-well plate in 500 µl of defined Neurobasal medium containing B27, Glutamax I, Albumax II and penicillin/streptomycin (Gibco-BRL, Carlsbad, CA, USA), supplemented with 100 ng/ml of 7.0S NGF per ml (Sigma, St. Louis, MO, USA). To model hyperglycemic conditions, 20 mM glucose was added to medium (45 mM total glucose) that did not contain B27.

Embryonic DRG Culture—DRG from 17-day rat embryos were cultured as previously described (Chattopadhyay et al., 2008). At 17 days in vitro the medium was changed to 45 mM glucose (20 mM glucose in addition to the basal 25 mM glucose) with Glutamax I, Albumax II, penicillin/streptomycin and NGF, but without B27. Control cells were exposed to identical medium lacking B27 with a total of 25 mM glucose.

Reagents—Bicuculline, (EC₅₀: 10–100 µM (Rho et al., 1996); Sigma, St. Louis, MO); phaclofen, (EC₅₀: 229–500 µM (Robinson et al., 1989; Shibuya et al., 1992); Biomol, Plymouth Meeting, PA); baclofen, (EC₅₀: 2.8–10 µM (Ong et al., 1990; Robinson et al., 1989); Sigma, St. Louis, MO); pertussis toxin (PTX; Tocris, Ellisville, MO); cholera toxin (CTX; Sigma, St. Louis, MO).

Western blot—Western blot was performed as previously described (Chattopadhyay et al., 2008) using the primary antibodies against Nav1.7 (1:400, Millipore, Bedford, MA); pPKCα/β (1:400 Cell Signaling, Beverly, MA); DOR (1:500 Millipore); GAD67 (1:500; Millipore); β-actin (1:2000; Sigma) and secondary horseradish peroxidase-conjugated anti-rabbit IgG or anti-mouse IgG (1:5,000 Amersham, Piscataway, NJ) visualized with ECL (Pierce, Rockford, IL). The intensity of each band was determined by quantitative chemiluminescence using a PC-based image analysis system (ChemiDoc XRS System, Bio-Rad Laboratories) and normalized to the respective level of β-actin. The specificity of the commercially obtained anti-Nav antibody for Nav1.7 was confirmed in primary neurons in culture using an HSV vector expressing an shRNA specific for Nav1.7 to selectively knock down Nav1.7 expression (Supplementary Figure 1).

RT-PCR—RNA was isolated using a commercial kit (MicroRNA; Stratagene, La Jolla, CA, USA). cDNA was transcribed from the mRNA at 37° C using a Sensiscript Reverse Transcriptase kit (Qiagen, Valencia, CA, USA) and RT-PCR completed using the following primers for Nav 1.7: forward, 5'-CCA TCA TGA ACG TGC TTC TCG TG-3'; reverse 5'-CAA AGC AAA GAG CAG AGT GCG GAT C-3' for 30 cycles of PCR as follows: 94° C for 1 min, 58°C for 2 min, 72° C for 1 min.

Immunocytochemistry—Immunocytochemistry was performed as previously described (Chattopadhyay et al., 2008) using the primary antibodies anti-GAD67 (1:1000; Chemicon, Temecula, CA, USA) or Nav1.7 (1:500; Neuromab; UC Davis, CA) and GABA_BR (1:400; Santa Cruz Biotechnology, Santa Cruz, CA) and the secondary fluorescent antibody, Alexa Fluor 594 goat anti-rabbit IgG (1:1000, Molecular Probes, Eugene, OR).

Statistical analysis—The statistical significance of the difference between groups was determined by ANOVA (Systat 9) using Bonferroni's correction for the multiple post hoc analyses. All results are expressed as mean ± SEM. All the tissue culture experiments were repeated 3 times. The animal experiments, with 8–10 animals per group, were repeated twice.

Results

HSV vector vG expresses GAD67 in DRG neurons in vitro and in vivo

Primary DRG neurons transduced at a multiplicity of infection (MOI) of 1 by vG showed a substantial increase in GAD67 expression compared to control or vZ-infected cells in vitro by Western blot and immunocytochemistry (Supplementary Figure 2). Following subcutaneous inoculation into the hind foot, rats inoculated with the vector vG showed increased GAD67 expression in lumbar DRG by Western blot and immunocytochemistry (7 days after vector inoculation; Supplementary Figure 2). In previous studies we have reported that infection of DRG with this non-replicating vector results in constitutive release of GABA from primary afferent terminals in the dorsal horn of spinal cord (Liu et al., 2006; Liu et al., 2004).

Continuous release of GABA reduces thermal hyperalgesia, mechanical hyperalgesia and cold allodynia in diabetic animals 4 weeks after inoculation of the vector vG

Diabetic animals demonstrated thermal hyperalgesia manifested by a decrease in withdrawal latency in response to noxious thermal stimuli (Figure 1a). Four weeks after inoculation of vG (6 weeks after diabetes) there was a statistically significant increase in thermal latency in vG treated animals compared to diabetic and control vector vZ-inoculated diabetic animals (Figure 1a). Diabetic rats also developed mechanical hyperalgesia 6 weeks after diabetes, and inoculation of vG significantly increased hind-paw withdrawal threshold compared to diabetic animals (Figure 1b) measured 4 week after inoculation. Diabetic animals inoculated with vZ showed no difference in mechanical threshold compared to diabetic animals (Figure 1b). Diabetic rats also developed cold allodynia 6 weeks after diabetes, with the latency to withdraw from the cold stimulus significantly decreased in diabetic compared to control animals (Figure 1c). Diabetic animals inoculated with vG showed a normal latency to withdraw from this stimulus (Figure 1c).

Vector mediated release of GABA prevents the increase in Nav1.7 and pPKCα/β in diabetic DRG in vivo

As reported previously (Chattopadhyay et al., 2008; Hong et al., 2004) there was a significant increase in Nav1.7 protein in diabetic compared to control DRG 6 weeks after diabetes (Figure 2). Animals inoculated with vG 2 wks after induction of diabetes by STZ

showed a substantial and significant reduction in the amount of Na_v1.7 in DRG at 4 wks after vector inoculation compared to animals inoculated with vZ (Figure 2b). Similarly, the amount of pPKC α/β was increased significantly in diabetic DRG compared to control, but in animals inoculated with vG 2 wks after induction of diabetes by STZ there was a substantial and significant reduction in the amount of pPKC α/β in DRG at 4 wks after vector inoculation (Figure 3a,b).

Modulation of Na_v1.7 by glucose in adult DRG neurons in vitro

In order to study the relationship of the amount of Na_v1.7 in DRG neurons to hyperglycemia we compared the adult DRG culture with primary E17 DRG neurons *in vitro*. The adult neurons constitutively express Na_v1.7 similar to primary embryonic DRG. After 18 hrs exposure to culture medium containing 45 mM glucose there was a substantial increase in the amount of Na_v1.7 protein in the adult DRG (Figure 4) that was similar to that seen in embryonic DRG in culture; the subsequent experiments were conducted using embryonic DRG neurons in order to minimize the number of animals that would need to be employed for these studies.

Continuous release of GABA by vG prevents the increase in Na_v1.7 expression and phosphorylation of PKC in primary DRG neurons in vitro exposed to hyperglycemia

Transfection of cells exposed to hyperglycemia with vG at an MOI of 1 blocked the increase in Na_v1.7 resulting from exposure to glucose (Figure 5a). There was a substantial increase in the amount of pPKC α/β in the primary DRG neurons exposed to hyperglycemic conditions. Transfection of cells exposed to hyperglycemia with vG at an MOI of 1 blocked the increase in phosphorylation resulting from exposure to hyperglycemic conditions in vitro (Figure 5b).

The effect of vector-mediated release of GABA on Na_v1.7 is reversed by phaclofen but not by bicuculline

In order to assess the relative contribution of GABA_A and GABA_B receptors in mediating the effects of vector-produced GABA, DRG neurons were transfected with vG at MOI of 1 and 24 hrs after transfection, exposed to 45 mM glucose along with either 50 μ M of bicuculline or 500 μ M phaclofen. Addition of bicuculline had no effect on the decrease in Na_v1.7 resulting from transfection with vG, (Figure 6a). In contrast, the effect of transfection with vG in preventing the increase in Na_v1.7 was completely blocked by the addition of 500 μ M phaclofen (Figure 6b). This finding was confirmed by experiments using the GABA_BR agonist baclofen. Addition of 10 μ M baclofen (Figure 6c) to primary DRG neurons exposed to hyperglycemia blocked the increase in Na_v1.7 resulting from hyperglycemia. Colocalization of GABA_BR and Na_v1.7 in individual DRG neurons *in vitro* was confirmed by double-label immunocytochemistry (Supplementary Figure 3).

GABA_B receptor-mediated regulation of voltage-gated sodium channel Na_v1.7 involves PKC in DRG neurons in vitro

We previously found that inhibition of PKC activation by addition of 10 μ M myristoylated PKC inhibitor 20–28 blocks the increase in Na_v1.7 in primary DRG neurons exposed to hyperglycemia (Chattopadhyay et al., 2008). To test whether the effect of GABA receptor activation proceeds through PKC, cells were transfected with vG at an MOI of 1, and 24 hrs after transfection exposed to 45 mM glucose along with either 50 μ M of bicuculline or 500 μ M phaclofen. Addition of bicuculline to vG-transfected cells exposed to hyperglycemic conditions resulted in no change in pPKC α/β , while the addition of phaclofen to vG-transfected cells prevented the vG effect of pPKC α/β (Figure 7a,b). These results support

that the vector mediated effect through the GABA_BR involves a block in phosphorylation of PKC downstream of GABA_BR activation.

Continuous activation of the GABA_BR by vector in reduction of Na_V 1.7 is mediated through activation of G $\alpha_{i/o}$ proteins

G proteins are the key signal transducing molecules for G-protein coupled receptors (GPCRs). Treatment of primary DRG neurons exposed to hyperglycemia with PTX (250 ng/ml overnight) blocked the effect of GABA_BR activation on the amount of Na_V1.7, but treatment with CTX (250 ng/ml overnight) did not result in any change in amount of Na_V 1.7 (Figure 8a, b). These results indicate that the effect of GABA on Na_V1.7 levels is mediated through G $\alpha_{i/o}$ proteins.

Discussion

There are two important observations in this study: 1) spinal release of GABA effected by transfection of DRG neurons *in vivo* with a GAD expressing vector reduces pain related behaviors in rats with PDN; and 2) continuous exposure to GABA reverses the increase in Na_V1.7 in primary sensory afferents that is characteristic of diabetic neuropathy through a GABA_BR mediated pathway.

HSV-mediated release of GABA reduces neuropathic pain related behaviors in rats with PDN

In previous reports we have demonstrated that subcutaneous inoculation of nonreplicating HSV-based vectors results in transfection of DRG neurons *in vivo* (Chattopadhyay et al., 2003; Goss et al., 2001), and that infection of DRG neurons with the HSV vector expressing GAD67 results in constitutive release of GABA (Liu et al., 2006; Liu et al., 2004). Transfection of DRG neurons *in vivo* with the HSV vector expressing GAD67 reduces pain related behaviors in the lateral hemisection model of central neuropathic pain (Liu et al., 2004) and in the selective spinal nerve ligation model of peripheral neuropathic pain (Hao et al., 2005). The results of the current study extend these findings to a model of the clinically prevalent neuropathic pain condition caused by diabetes.

Tonic spinal GABAergic inhibition plays an important role in the modulation of basal pain sensation. Intrathecal bicuculline in normal animals produces hyperalgesia (Hwang and Yaksh, 1997), and reductions in both GAD and GABA in dorsal horn have been reported in models of pain created by peripheral nerve injury (Castro-Lopes et al., 1993; Eaton et al., 1998; Ibuki et al., 1997; Moore et al., 2002). In addition to our studies with HSV mediated gene transfer of GAD, direct injection of an adeno-associated virus-based vector expressing GAD65 into DRG neurons reduces pain related symptoms in animals with neuropathic pain (Lee et al., 2007) and intrathecal administration of baclofen produces an antinociceptive effect in acute pain (Dirig and Yaksh, 1995; Malcangio and Bowery, 1995; Smith et al., 1994), in animal models of pain following nerve injury (Castro-Lopes et al., 1995; Engle et al., 2006; Smith et al., 1994; Yang, 2004) and in rats with PDN (Malcangio and Tomlinson, 1998).

GABA acting through the GABA_A receptor may also function as an excitatory neurotransmitter as it does during development or in conditions characterized by a reduction in the expression of KCC2 (Coull et al., 2003; Zhang et al., 2008) including PDN (Jolivald et al., 2008). How might we reconcile the differences between the evidence that GABA may function as an excitatory neurotransmitter in PDN with the current studies demonstrating that transgene-mediated release of GABA in the dorsal horn results in a reduction in pain related behaviors? One possibility regards the distinct but overlapping roles played by

GABA_A and GABA_B receptors. While changes in KCC2 will result in a change the reversal potential of the GABA_AR this change would not be expected to have an effect on GABA_BR function. The observations in our current study, indicating that vector-mediated release of GABA results in a reduction in pain-related behaviors in the rat likely reflects presynaptic GABA_BR effects, since the effect of GABA in preventing the increase in Nav1.7 in the DRG of diabetic rats is clearly presynaptic, though the possible additional role of postsynaptic effects cannot be excluded.

Nav1.7 in DRG neurons plays an important role in neuropathic pain

Neuropathic pain results from hyperexcitability of primary afferent nociceptors that may result from electrical discharges at the site of axonal injury or ectopic/spontaneous activity in DRG neurons (Baron, 2000; Devor, 2006; Sukhotinsky et al., 2004). Voltage gated sodium channel isoforms expressed in nociceptive neurons participate in fine tuning the firing properties of nociceptors (Devor, 2006; Lai et al., 2003), and among these isoforms there is evidence that Nav1.7 in DRG neurons, plays a critical role in the pathogenesis of neuropathic pain (Black et al., 2004; Cummins et al., 2007; Ekberg and Adams, 2006; Wilson-Gerwing et al., 2008). Gain of function mutations in the SCN9A gene coding for Nav1.7 leads to conditions characterized by spontaneous pain including primary erythralgia and paroxysmal extreme pain disorder (Dib-Hajj et al., 2007; Drenth and Waxman, 2007); loss of function mutations in SCN9A results in an inherited channelopathy characterized by congenital insensitivity to pain (Cox et al., 2006); and hyperexcitability of primary afferents in human PDN is associated with increased internodal sodium currents (Misawa et al., 2009).

In rats with STZ-induced diabetes the amount of Nav1.7 protein in DRG neurons is increased (Chattopadhyay et al., 2008; Hong et al., 2004), and alterations in physiologic properties of the DRG neurons from diabetic rats with PDN concordant with this increase have been defined (Hong et al., 2004). The embryonic Nav isoform Nav1.3 is also increased in DRG of diabetic animals (Hong et al., 2004), but the total amount of Nav1.3 in DRG neurons is very low, and unlikely to contribute significantly to the pain phenotype. Other isoforms present in DRG neurons, such as Nav1.8, are reduced in animals with PDN and unlikely to play an important role in the pathogenesis of pain in these animals. While final proof that neuropathic pain in diabetic animals results from the increase in Nav1.7 will require selective knock-down of Nav1.7 or selective interference with Nav1.7 function, taken together, the evidence from inherited forms of neuropathic pain and the observations in animals with PDN strongly implicate increases in Nav1.7 protein in pathogenesis of neuropathic pain in this condition. The results presented here do not exclude the possibility that alterations in the biophysical properties of voltage gated sodium channels resulting from phosphorylation or other post-translational modifications may also play a role in increasing electrical excitability of peripheral afferents in diabetic animals, but experiments to investigate these effects are beyond the scope of the current investigation.

GABA_BR activation and Nav protein levels

The observation that GABA prevents the increase in Nav1.7 in the DRG of diabetic animals provides a second means through which GABA may be reducing neuropathic pain in these animals. Considered in conjunction with our previous study showing that continuous release of the inhibitory neurotransmitter enkephalin in diabetic animals reduces pain coincident with a reduction in Nav1.7 levels in DRG neurons through activation of the DOR (Chattopadhyay et al., 2008), the current results suggests the existence of a novel common mechanism of presynaptic GPCR regulation of voltage gated channel protein levels. Bicuculline block of the GABA_A receptor had no effect on vector-mediated GABA release reduction in Nav1.7 protein in DRG neurons exposed to hyperglycemic conditions. While

this does not entirely exclude the possibility of a GABA_A receptor-mediated effect that might be observed using other doses of the inhibitor, taken together the results of the in vitro experiments clearly support a role for GABA acting through the GABA_B receptor on regulating Na_v1.7 levels.

Implications of the regulation of Na_v 1.7 by GPCR

The data in the current report indicate that vector-mediated release of GABA may provide an analgesic effect in PDN through at least two distinct mechanisms: actions as an inhibitory neurotransmitter as well as distinct effects to reduce the amount of Na_v1.7 in DRG neurons. Whether there are other changes in DRG phenotype produced by continuous GABA_B or GABA_A receptor activation is beyond the scope of the current experiments, but may be interesting to explore in the future. However, the findings that reveal a previously unrecognized relationship between this presynaptic GPCR and the level of the voltage-gated channel in the primary sensory neuron have potential implications for the regulation of these channels in normal homeostasis. Taken together with our previous findings of a similar relationship between continuous activation of the DOR GPCR and Na_v1.7 levels in DRG neurons, the results suggest that it is possible that continuous activation of GPCR in vivo by release of endogenous neurotransmitters may regulate the steady state levels of voltage gated ion channels, and in addition provide insight that may be useful in designing therapies to treat painful diabetic neuropathy.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We acknowledge the technical assistance of Vikram Thakur Singh in vector propagation, Shue Liu in tissue culture, Katie Maier in overall experiments, Len Cooke and Jere Christian in the animal work. This work was funded by grants from the National Institutes of Health and the Department of Veterans Affairs to DJF and MM. The authors have no competing financial interests to declare.

References

- Baron R. Peripheral neuropathic pain: from mechanisms to symptoms. *Clin J Pain*. 2000; 16:S12–20. [PubMed: 10870735]
- Black JA, Liu S, Tanaka M, Cummins TR, Waxman SG. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. *Pain*. 2004; 108:237–247. [PubMed: 15030943]
- Castro-Lopes JM, Malcangio M, Pan BH, Bowery NG. Complex changes of GABAA and GABAB receptor binding in the spinal cord dorsal horn following peripheral inflammation or neurectomy. *Brain Res*. 1995; 679:289–297. [PubMed: 7633890]
- Castro-Lopes JM, Tavares I, Coimbra A. GABA decreases in the spinal cord dorsal horn after peripheral neurectomy. *Brain Res*. 1993; 620:287–291. [PubMed: 8369960]
- Chattopadhyay M, Goss J, Lacomis D, Goins W, Glorioso JC, Mata M, Fink DJ. Protective effect of HSV-mediated gene transfer of nerve growth factor in pyridoxine neuropathy demonstrates functional activity of trkA receptors in large sensory neurons of adult animals. *Eur J Neurosci*. 2003; 17:732–740. [PubMed: 12603263]
- Chattopadhyay M, Mata M, Fink DJ. Continuous delta opioid receptor activation reduces neuronal voltage gated sodium channel (Na_v1.7) levels through activation of protein kinase C in painful diabetic neuropathy. *J Neurosci*. 2008; 28:6652–6658. [PubMed: 18579738]
- Coull JA, Boudreau D, Bachand K, Prescott SA, Nault F, Sik A, De Koninck P, De Koninck Y. Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. *Nature*. 2003; 424:938–942. [PubMed: 12931188]

- Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, Karbani G, Jafri H, Mannan J, Raashid Y, Al-Gazali L, Hamamy H, Valente EM, Gorman S, Williams R, McHale DP, Wood JN, Gribble FM, Woods CG. An SCN9A channelopathy causes congenital inability to experience pain. *Nature*. 2006; 444:894–898. [PubMed: 17167479]
- Cummins TR, Sheets PL, Waxman SG. The roles of sodium channels in nociception: Implications for mechanisms of pain. *Pain*. 2007; 131:243–257. [PubMed: 17766042]
- Devor M. Sodium channels and mechanisms of neuropathic pain. *J Pain*. 2006; 7:S3–S12. [PubMed: 16426998]
- Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. From genes to pain: Nav 1.7 and human pain disorders. *Trends Neurosci*. 2007; 30:555–563. [PubMed: 17950472]
- Dirig DM, Yaksh TL. Intrathecal baclofen and muscimol but not midazolam, are antinociceptive using the rat-formalin model. *J Pharmacol Exp Ther*. 1995; 275:219–227. [PubMed: 7562553]
- Drenth JP, Waxman SG. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. *J Clin Invest*. 2007; 117:3603–3609. [PubMed: 18060017]
- Eaton MJ, Plunkett JA, Karmally S, Martinez MA, Montanez K. Changes in GAD-and GABA-immunoreactivity in the spinal dorsal horn after peripheral nerve injury and promotion of recovery by lumbar transplant of immortalized serotonergic precursors. *J Chem Neuroanat*. 1998; 16:57–72. [PubMed: 9924973]
- Ekberg J, Adams DJ. Neuronal voltage-gated sodium channel subtypes: key roles in inflammatory and neuropathic pain. *Int J Biochem Cell Biol*. 2006; 38:2005–2010. [PubMed: 16919992]
- Engle MP, Gassman M, Sykes KT, Bettler B, Hammond DL. Spinal nerve ligation does not alter the expression or function of GABA(B) receptors in spinal cord and dorsal root ganglia of the rat. *Neuroscience*. 2006; 138:1277–1287. [PubMed: 16427742]
- Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. *Pain*. 2010; 150:573–581. [PubMed: 20705215]
- Glorioso JC, Fink DJ. Herpes vector-mediated gene transfer in treatment of diseases of the nervous system. *Annu Rev Microbiol*. 2004; 58:253–271. [PubMed: 15487938]
- Goss JR, Harley CF, Mata M, O'Malley ME, Goins WF, Hu X-P, Glorioso JC, Fink DJ. Herpes vector-mediated expression of proenkephalin reduces pain-related behavior in a model of bone cancer pain. *Ann Neurol*. 2002; 52:662–665. [PubMed: 12402268]
- Goss JR, Mata M, Goins WF, Wu HH, Glorioso JC, Fink DJ. Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. *Gene Ther*. 2001; 8:551–556. [PubMed: 11319622]
- Hao S, Mata M, Goins W, Glorioso JC, Fink DJ. Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect. *Pain*. 2003; 102:135–142. [PubMed: 12620604]
- Hao S, Mata M, Wolfe D, Glorioso JC, Fink DJ. Gene transfer of glutamic acid decarboxylase reduces neuropathic pain. *Ann Neurol*. 2005; 57:914–918. [PubMed: 15929041]
- Hao S, Wolfe D, Glorioso JC, Mata M, Fink DJ. Effects of transgene-mediated endomorphin-2 in inflammatory pain. *Eur J Pain*. 2009; 13:380–386. [PubMed: 18567517]
- Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. *Pain*. 1988; 32:77–88. [PubMed: 3340425]
- Hong S, Morrow TJ, Paulson PE, Isom LL, Wiley JW. Early painful diabetic neuropathy is associated with differential changes in tetrodotoxin-sensitive and -resistant sodium channels in dorsal root ganglion neurons in the rat. *J Biol Chem*. 2004; 279:29341–29350. [PubMed: 15123645]
- Hong S, Wiley JW. Altered expression and function of sodium channels in large DRG neurons and myelinated A-fibers in early diabetic neuropathy in the rat. *Biochem Biophys Res Commun*. 2006; 339:652–660. [PubMed: 16310161]
- Hwang JH, Yaksh TL. The effect of spinal GABA receptor agonists on tactile allodynia in a surgically-induced neuropathic pain model in the rat. *Pain*. 1997; 70:15–22. [PubMed: 9106805]
- Ibuki T, Hama AT, Wang XT, Pappas GD, Sagen J. Loss of GABA-immunoreactivity in the spinal dorsal horn of rats with peripheral nerve injury and promotion of recovery by adrenal medullary grafts. *Neuroscience*. 1997; 76:845–858. [PubMed: 9135056]

- Jolival CG, Lee CA, Ramos KM, Calcutt NA. Allodynia and hyperalgesia in diabetic rats are mediated by GABA depletion of spinal potassium-chloride co-transporters. *Pain*. 2008; 140:48–57. [PubMed: 18755547]
- Lai J, Hunter JC, Porreca F. The role of voltage-gated sodium channels in neuropathic pain. *Curr Opin Neurobiol*. 2003; 13:291–297. [PubMed: 12850213]
- Lee B, Kim J, Kim SJ, Lee H, Chang JW. Constitutive GABA expression via a recombinant adeno-associated virus consistently attenuates neuropathic pain. *Biochem Biophys Res Commun*. 2007; 357:971–976. [PubMed: 17466264]
- Liu J, Tai C, de Groat WC, Peng XM, Mata M, Fink DJ. Release of GABA from sensory neurons transduced with a GAD67-expressing vector occurs by non-vesicular mechanisms. *Brain Res*. 2006; 1073–1074:297–304.
- Liu J, Wolfe D, Hao S, Huang S, Glorioso JC, Mata M, Fink DJ. Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain. *Mol Ther*. 2004; 10:57–66. [PubMed: 15233942]
- Malcangio M, Bowery NG. Possible therapeutic application of GABAB receptor agonists and antagonists. *Clin Neuropharmacol*. 1995; 18:285–305. [PubMed: 8665542]
- Malcangio M, Tomlinson DR. A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats. *Pain*. 1998; 76:151–157. [PubMed: 9696468]
- Mantyh PW, Hunt SP. Setting the tone: superficial dorsal horn projection neurons regulate pain sensitivity. *Trends Neurosci*. 2004; 27:582–584. [PubMed: 15374667]
- Mata M, Hao S, Fink DJ. Applications of gene therapy to the treatment of chronic pain. *Curr Gene Ther*. 2008; 8:42–48. [PubMed: 18336248]
- Misawa S, Sakurai K, Shibuya K, Iose S, Kanai K, Ogino J, Ishikawa K, Kuwabara S. Neuropathic pain is associated with increased nodal persistent Na(+) currents in human diabetic neuropathy. *J Peripher Nerv Syst*. 2009; 14:279–284. [PubMed: 20021569]
- Moore KA, Kohno T, Karchewski LA, Scholz J, Baba H, Woolf CJ. Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. *J Neurosci*. 2002; 22:6724–6731. [PubMed: 12151551]
- Ong J, Harrison NL, Hall RG, Barker JL, Johnston GA, Kerr DI. 3-Aminopropanephosphinic acid is a potent agonist at peripheral and central presynaptic GABAB receptors. *Brain Res*. 1990; 526:138–142. [PubMed: 1964105]
- Randall LO, Sellito JJ. A method for measurement of analgesic activity on inflamed tissue. *Arch Int Pharmacodyn Ther*. 1957; 111:409–419. [PubMed: 13471093]
- Rho JM, Donevan SD, Rogawski MA. Direct activation of GABAA receptors by barbiturates in cultured rat hippocampal neurons. *J Physiol*. 1996; 497 (Pt 2):509–522. [PubMed: 8961191]
- Robinson TN, Cross AJ, Green AR, Toczek JM, Boar BR. Effects of the putative antagonists phaclofen and delta-aminovaleic acid on GABAB receptor biochemistry. *Br J Pharmacol*. 1989; 98:833–840. [PubMed: 2556202]
- Shibuya I, Kongsamut S, Douglas WW. Effectiveness of GABAB antagonists in inhibiting baclofen-induced reductions in cytosolic free Ca concentration in isolated melanotrophs of rat. *Br J Pharmacol*. 1992; 105:893–898. [PubMed: 1324054]
- Smith GD, Harrison SM, Birch PJ, Elliott PJ, Malcangio M, Bowery NG. Increased sensitivity to the antinociceptive activity of (+/-)-baclofen in an animal model of chronic neuropathic, but not chronic inflammatory hyperalgesia. *Neuropharmacology*. 1994; 33:1103–1108. [PubMed: 7838323]
- Sukhotinsky I, Ben-Dor E, Raber P, Devor M. Key role of the dorsal root ganglion in neuropathic tactile hypersensitivity. *Eur J Pain*. 2004; 8:135–143. [PubMed: 14987623]
- Tavakoli M, Mojaddidi M, Fadavi H, Malik RA. Pathophysiology and treatment of painful diabetic neuropathy. *Curr Pain Headache Rep*. 2008; 12:192–197. [PubMed: 18796269]
- Wilson-Gerwing TD, Stucky CL, McComb GW, Verge VM. Neurotrophin-3 significantly reduces sodium channel expression linked to neuropathic pain states. *Exp Neurol*. 2008; 213:303–314. [PubMed: 18601922]

- Wolfe D, Goins WF, Yamada M, Moriuchi S, Krisky DM, Oligino TJ, Marconi PC, Fink DJ, Glorioso JC. Engineering herpes simplex virus vectors for CNS applications. *Exp Neurol*. 1999; 159:34–46. [PubMed: 10486173]
- Wolfe D, Hao S, Hu J, Srinivasan R, Goss J, Mata M, Fink DJ, Glorioso JC. Engineering an endomorphin-2 gene for use in neuropathic pain therapy. *Pain*. 2007; 133:29–38. [PubMed: 17395375]
- Wolfe D, Mata M, Fink DJ. A human trial of HSV-mediated gene transfer for the treatment of chronic pain. *Gene Ther*. 2009; 16:455–460. [PubMed: 19242524]
- Yang XL. Characterization of receptors for glutamate and GABA in retinal neurons. *Prog Neurobiol*. 2004; 73:127–150. [PubMed: 15201037]
- Zhang W, Liu LY, Xu TL. Reduced potassium-chloride co-transporter expression in spinal cord dorsal horn neurons contributes to inflammatory pain hypersensitivity in rats. *Neuroscience*. 2008; 152:502–510. [PubMed: 18262726]

Figure 1. Vector mediated expression of GABA reverses pain-related behaviors in animals with PDN

(a) Thermal withdrawal latency (Hargreave's test) in seconds. (b) Mechanical hyperalgesia (Randall Selitto test) threshold in grams. (c) Cold allodynia in seconds. C – naïve control; D - diabetic; DvG - diabetic inoculated with vG; DvZ - diabetic inoculated with vZ; all data presented as mean $\pm$ SEM, $n = 6-8$ per group. # $P < 0.0001$ or *** $P < 0.001$ vs. untreated diabetic animals or DvZ.

Figure 2. vG mediated GABA expression attenuates the increase in Nav1.7 in DRG *in vivo* characteristic of PDN

Amount of Nav1.7 determined by Western blot, normalized to D (a) or DvZ (b). C - control; D - diabetic; DvG - diabetic inoculated with vG; DvZ - diabetic inoculated with vZ; *** $P < 0.001$ or * $P < 0.01$; $n = 5$ animals per group. Representative Western blots showing one sample from each group are presented above each graph.

Figure 3. Inoculation of vG prevents phosphorylation of PKC in diabetic DRG *in vivo*
 Amount of pPKCα/β determined by Western blot, normalized to D (a) or DvZ (b). ** $P < 0.005$; $n = 5$ animals per group. C - Control; D - diabetic; DvG - diabetic inoculated with vG; DvZ - diabetic inoculated with vZ. Representative Western blots showing one sample from each group are presented above each graph.

Figure 4. Na_V1.7 levels are increased in adult DRG neurons in culture exposed to hyperglycemic conditions

Adult DRG neurons in culture were exposed to medium containing 45 mM glucose for 18 hrs, and the amount of Na_V1.7 determined by Western blot.

Figure 5. Transgene-mediated expression of GABA prevents the increase in Nav1.7 in primary DRG neurons exposed to hyperglycemic conditions *in vitro*

(a) Significant reduction in the amount of Nav1.7 in hyperglycemic neurons treated with vG as determined by Western blot, normalized to G. (b) Amount of pPKC α /β determined by Western blot, normalized to C. ** $P < 0.005$ or * $P < 0.01$; C - control; G - hyperglycemia; GvG – hyperglycemia, transfected with vG. Representative Western blots showing one sample from each group are presented above each graph.

Figure 6. Phaclofen but not bicuculline blocks the effect of vG on the amount Na_V1.7 in DRG neurons exposed to hyperglycemic conditions *in vitro*

(a) No substantial changes in the amount of Na_V1.7 in primary DRG neurons exposed to hyperglycemia, transfected with vG in the presence of 50 μM of bicuculline (vG + bic). (b) Significant changes in the amount of Na_V1.7 in primary DRG neurons exposed to hyperglycemia and transfected with vG in the presence of 500 μM of phaclofen (vG + phac), normalized to vG; (c) Substantial changes in the amount of Na_V1.7 in primary DRG neurons exposed to hyperglycemia in the presence of 10 μM of baclofen (G + bac). G - hyperglycemia; vG - cells transfected with vector; vG + phac- cells transfected with vG in presence of phaclofen; vG + bic- cells transfected with vG in presence of bicuculline, G +

bac- hyperglycemia, in presence of baclofen. $*P < 0.01$, $**P < 0.005$. Representative Western blots showing one sample from each group are presented above each graph.

Figure 7. Phosphorylation of PKC in hyperglycemic DRG neurons is blocked by a GABA_BR antagonist

(a) No changes in pPKC α/β in primary DRG neurons exposed to 45 mM glucose and transfected with vG in the presence of 50 μ M bicuculline (vG + bic) compared to vG treated neurons; (b) There were significant changes in the amount of pPKC α/β in primary DRG neurons exposed to 45 mM glucose and transfected with vG in the presence of 500 μ M phaclofen (vG + phac) compared to vG treated neurons; * $P < 0.01$, ** $P < 0.005$; $n = 3$ wells per group. Representative Western blots showing one sample from each group are presented above each graph.

Figure 8. Effect of continuous activation of GABA_BR by vG on levels of Na_V1.7 is mediated through G_{i/o} proteins

(a) Treatment with of vG-infected neurons exposed to hyperglycemic conditions with pertussis toxin (PTX; 250 ng/ml) reversed the effect of GABA_BR activation on the amount of Na_V1.7 compared to vG infected neurons exposed to hyperglycemic conditions ** $P < 0.005$. (b) Treatment with cholera toxin (CTX) in similar conditions did not result in any change in amount of Na_V1.7 in vG infected DRG neurons * $P < 0.01$.